^
No biomarker
Multiple Myeloma
ciltacabtagene autoleucel
Sensitive: A1 - Approval
J&J Press Release - 2 days - (New A1)
No biomarker
Multiple Myeloma
selinexor
Sensitive: A1 - Approval
Karyopharm Press Release - 1 week - (New B)
No biomarker
Multiple Myeloma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
Chr amplification(1)(q21)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
Chr t(14;16)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
Chr t(4;14)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
Chr del(17p)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
MAGEC1 expression
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
miR-16 underexpression
Multiple Myeloma
RD
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
MCT1 overexpression + SLC16A3 overexpression
Multiple Myeloma
metformin + syrosingopine
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
carfilzomib
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
SVd
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
pomalidomide
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
thalidomide
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
prednisone + thalidomide + melphalan
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
lenalidomide + daratumumab / hyaluronidase
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
lenalidomide + daratumumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
daratumumab / hyaluronidase
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
lenalidomide
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
VTD
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
belantamab mafodotin
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
denosumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
melphalan flufenamide
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
lenalidomide + carfilzomib
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
daratumumab + pomalidomide
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
daratumumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
idecabtagene vicleucel
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
zoledronic acid
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
daratumumab + thalidomide
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
thalidomide + daratumumab / hyaluronidase
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
pomalidomide + daratumumab / hyaluronidase
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
dexamethasone tablets
Sensitive: A1 - Approval
Chr t(11;14)
Multiple Myeloma
venetoclax
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
lenalidomide + bortezomib
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
bortezomib + elotuzumab
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
D-VTd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
ixazomib
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
RD
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
VMP
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
VRD
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
bendamustine
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
melphalan
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
venetoclax + dexamethasone
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
cyclophosphamide
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
panobinostat
Sensitive: A2 - Guideline
Chr del(17)(p13)
Multiple Myeloma
bortezomib
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
PVD
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
EloRd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
IRd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
KRd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
DRd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
DVMP
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
CyBorD
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
EloPd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
Isa-PD
Sensitive: A2 - Guideline
Chr t(11;14)
Multiple Myeloma
VenVd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
DVD
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
IsaKd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
DKd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
DCEP
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
selinexor + pomalidomide
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
selinexor + daratumumab
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
BVD
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
BRD
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
ixazomib + pomalidomide
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
pomalidomide
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
D-KRd
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
selinexor + carfilzomib
Sensitive: A2 - Guideline
No biomarker
Multiple Myeloma
galinpepimut-S
Sensitive: B - Late Trials
Chr amplification(1q)
Multiple Myeloma
VRD
Resistant: B - Late Trials
Chr t(11;14)
Multiple Myeloma
venetoclax + bortezomib
Sensitive: B - Late Trials
Chr del(17p)
Multiple Myeloma
bortezomib + selinexor
Sensitive: B - Late Trials
No biomarker
Multiple Myeloma
KD
Sensitive: B - Late Trials
No biomarker
Multiple Myeloma
VD
Sensitive: B - Late Trials
Chr del(17p)
Multiple Myeloma
DVD
Sensitive: B - Late Trials
Chr t(14;16)
Multiple Myeloma
DVD
Sensitive: B - Late Trials
Chr t(4;14)
Multiple Myeloma
DVD
Sensitive: B - Late Trials
Chr del(17p)
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: B - Late Trials
CD38 expression
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
No biomarker
Multiple Myeloma
venetoclax + bortezomib + dexamethasone
Sensitive: B - Late Trials
Chr del(17p)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
Chr t(14;16)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
Chr t(4;14)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
BCL2 overexpression
Multiple Myeloma
venetoclax
Sensitive: B - Late Trials
No biomarker
Multiple Myeloma
PBCAR269A
Sensitive: B - Late Trials
TNFRSF17 expression
Multiple Myeloma
belantamab mafodotin
Sensitive: B - Late Trials
RPL5 expression
Multiple Myeloma
bortezomib
Sensitive: B - Late Trials
No biomarker
Multiple Myeloma
selinexor
Sensitive: B - Late Trials
No biomarker
Multiple Myeloma
ALLO-715
Sensitive: B - Late Trials
Chr t(11;14)
Multiple Myeloma
TD
Resistant: B - Late Trials
Chr t(11;14)
Multiple Myeloma
VTD
Resistant: B - Late Trials
No biomarker
Multiple Myeloma
JNJ-64007957
Sensitive: B - Late Trials
Chr amplification(1)(q21)
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: B - Late Trials